The CBSE Class 10 and Class 12 board examinations will begin on February 17. The Class 10 exams will end on March 10, while Class 12 exams will conclude on April 9. Ahead of the board exams, CBSE ...
Even beyond the pendulum lurches between presidencies, many of the perennial debates over education policy, politics, and ...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...
Opinion
ZNetwork on MSNOpinion
Social strikes: Can general strikes, mass strikes, and people power uprisings provide a last defense against MAGA tyranny?
Jeremy Brecher is a co-founder and senior strategic advisor for the Labor Network forSustainability. He is the author of more than fifteen books on labor and social movements,including Strike! Common ...
Adyton Resources Corp. is pleased to announce that it has received a Non-Binding LOI from Korean group Hyosung TNC Corporation on 8, 2025 for the purchase of gold concentrate from its Wapolu Gold ...
Copper Quest Exploration Inc. is pleased to announce that, further to its news release dated 1, 2025, it has issued an aggregate of 10,142,104 flow-through shares of the Company at a price of $0.19 ...
I know it can be irritating to be asked to subscribe to get additional information – especially when you've relied on Moneyweb's free data for years. But the cost of sourcing th ...
People living with HIV were among the hardest hit.
As Congress races to decide the future of the Affordable Care Act's enhanced premium tax credits, Iowa's delegation remains ...
States and cities can advance these 21 ideas in 2026 to build worker power, support unionized workers, and uphold workforce stability and standards. Members of UAW Local 230 and their supporters walk ...
Anglo American plc (‘Anglo American’) notes the announcement by Teck Resources Limited (‘Teck’) on the results of its shareholder vote at the special meeting where the proposed merger of equals with ...
Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results